|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1703.80
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | 5,271.40 | -1,615.30 | 16,297.00 | 10,522.50 | 23,423.70 | Adjustment | 5,837.90 | 4,493.60 | 4,870.60 | 7,185.40 | 6,573.10 | Changes In working Capital | 8,098.60 | -2,849.70 | -1,180.40 | 8,346.20 | 9,223.50 | Cash Flow after changes in Working Capital | 19,207.90 | 28.60 | 19,987.20 | 26,054.10 | 39,220.30 | Cash Flow from Operating Activities | 17,939.90 | 1,510.30 | 15,700.80 | 22,194.90 | 31,107.20 | Cash Flow from Investing Activities | -12,691.70 | -3,717.90 | -25,075.20 | -7,395.60 | -28,650.70 | Cash Flow from Financing Activities | -4,982.60 | 1,024.50 | -531.70 | -3,678.50 | -2,953.80 | Net Cash Inflow / Outflow | 265.60 | -1,183.10 | -9,906.10 | 11,120.80 | -497.30 | Opening Cash & Cash Equivalents | 591.00 | 1,774.10 | 11,680.20 | 559.40 | 1,056.70 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 0 | 0 | 0 | 0 | 0 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | 0 | 0 | 0 | 0 | 0 | Closing Cash & Cash Equivalent | 856.60 | 591.00 | 1,774.10 | 11,680.20 | 559.40 |
|
|
|
|
|
|